Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$3.03 USD
-0.06 (-1.80%)
Updated Jun 11, 2024 09:55 AM ET
After-Market: $3.07 +0.04 (1.17%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Aytu BioPharma Inc. [AYTU]
Reports for Purchase
Showing records 21 - 40 ( 40 total )
Company: Aytu BioPharma Inc.
Industry: Unclassified
Clinical Findings of MiOXSYS Presented; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Clinical Findings of MiOXSYS Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Dropping coverage due to termination of services.
Provider: Taglich Brothers, Inc.
Company: Aytu BioPharma Inc.
Industry: Unclassified
FY2017 3Q Financial Results; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Aytu BioPharma Inc.
Industry: Unclassified
FY2017 3Q Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Acquisition of a Commercialized Consumer Product in Female Sexual Health; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Acquisition of a Commercialized Consumer Product in Female Sexual Health; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Initiating as Speculative Buy with a 12-month price target of $1.25 per share based on a year-ahead value of projected FY19 ends June 2019 revenue per share.
Provider: Taglich Brothers, Inc.
Analyst: NOBLE J
Company: Aytu BioPharma Inc.
Industry: Unclassified
Natesto? Prescription Continues Growth; Potential Breakeven in Summer 2018; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Natesto Prescription Continues Growth; Potential Breakeven in Summer 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Regulatory Outlook for Secondary Hypogonadism Remains Favorable; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Regulatory Outlook for Secondary Hypogonadism Remains Favorable; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Natesto? Adoption Ramps Up; Significantly Increased Marketing Spend; Reiterate Buy and Lowering Price Target to $2.50
Provider: H.C. Wainwright & Co., Inc.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Natesto Adoption Ramps Up; Significantly Increased Marketing Spend; Reiterate Buy and Lowering Price Target to $2.50
Provider: Rodman & Renshaw, Co.
Company: Aytu BioPharma Inc.
Industry: Unclassified
Company: Aytu BioPharma Inc.
Industry: Unclassified
We are initiating coverage at Buy With $9 Price Target
Provider: Rodman & Renshaw, Co.
Company: Aytu BioPharma Inc.
Industry: Unclassified
A Rapidly-Growing Urology Company; Initiating at Buy With $9 Price Target
Provider: H.C. Wainwright & Co., Inc.